# Insight Molecular (IMDX) — Earnings

IMDX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/imdx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.23 |
| EPS estimate | −$0.24 |
| EPS surprise | +4.17% |
| Revenue surprise | −45.37% |
| Revenue | $239,000.00 |
| Revenue estimate | $437,500.00 |
| Reported | Aug 10, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1642380/000164238026000011/imdx-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/2d26a56f-f257-1132-c2fb-37b862be8d27.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 10, 2026 | −$0.24 | −$0.23 | 4.17% | $437,500.00 | $239,000.00 |
| Q1 2026 | May 13, 2026 | −$0.26 | −$0.28 | -7.07% | $229,225.00 | $32,000.00 |
| Q4 2025 | Mar 26, 2026 | −$0.24 | −$0.27 | -13.68% | $285,000.00 | $1.1M |
| Q3 2025 | Nov 10, 2025 | −$0.21 | −$0.20 | 4.71% | $283,900.00 | $260,000.00 |
| Q2 2025 | Aug 11, 2025 | −$0.23 | −$0.30 | -30.43% | $292,500.00 | $518,000.00 |
| Q1 2025 | May 12, 2025 | −$0.24 | −$0.26 | -9.47% | $127,500.00 | $2.1M |
| Q4 2024 | Mar 24, 2025 | −$0.40 | −$1.93 | -382.50% | $101,667.00 | $1.5M |
| Q3 2024 | Nov 12, 2024 | −$0.44 | −$0.40 | 7.99% | $178,333.00 | $115,000.00 |
| Q2 2024 | Aug 8, 2024 | −$0.56 | −$0.38 | 31.29% | $318,550.00 | $104,000.00 |
| Q1 2024 | May 15, 2024 | −$0.67 | −$0.62 | 7.81% | $350,000.00 | $176,000.00 |
| Q4 2023 | Apr 12, 2024 | −$0.70 | −$2.27 | -224.29% | $225,000.00 | $314,000.00 |
| Q3 2023 | Nov 9, 2023 | −$1.01 | −$0.81 | 19.67% | $312,500.00 | $429,000.00 |
| Q2 2023 | Aug 10, 2023 | −$1.30 | −$1.07 | 17.53% | $362,500.00 | $463,000.00 |
| Q1 2023 | May 11, 2023 | −$1.80 | $0.40 | 122.22% | $346,400.00 | $297,000.00 |
| Q3 2022 | Nov 10, 2022 | −$2.27 | −$1.69 | 25.34% | $1.5M | $1.0M |
| Q2 2022 | Aug 10, 2022 | −$2.40 | −$1.40 | 41.67% | $2.7M | $2.1M |
| Q1 2022 | May 11, 2022 | −$2.43 | −$2.20 | 9.41% | $2.2M | $1.4M |
| Q4 2021 | Mar 10, 2022 | −$2.46 | −$7.80 | -217.45% | $3.5M | $3.6M |
| Q3 2021 | Nov 9, 2021 | −$2.30 | −$3.00 | -30.41% | $1.8M | $984,000.00 |
| Q2 2021 | Aug 10, 2021 | −$2.01 | −$2.40 | -19.34% | $1.6M | $2.0M |

## Frequently Asked Questions

### When did Insight Molecular (IMDX) last report earnings?

Insight Molecular last reported on Aug 10, 2026, covering fiscal Q2 2026.

### Did IMDX beat earnings estimates?

Yes. Insight Molecular reported EPS of −$0.23 for Q2 2026 against a −$0.24 estimate — a 4.17% beat.

### How much revenue did IMDX report last quarter?

Insight Molecular reported $239,000.00 in revenue for Q2 2026, against a consensus estimate of $437,500.00.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).